Results 231 to 240 of about 48,011 (257)

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Lancet, The, 2021
Christopher J Sweeney Mbbs, Sergio Bracarda, Cora N Sternberg   +2 more
exaly  

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Lancet, The, 2021
Jong-Mu Sun, Manish A Shah, Toshihiko Doi   +2 more
exaly  

Citotoksičnost i brtvljenje Roekoseal i AH Plus punila korijenskog kanala

2005
s
openaire   +1 more source

Ocena kliniczna uszczelniacza AH Plus

Magazyn Stomatologiczny, 1998
Luciński, Rafał, Szczepankiewicz, Włodzimierz   +1 more
openaire  

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Lancet, The, 2019
Stefan Kasper, Hans-Georg Kopp, Georg Martin Haag   +2 more
exaly  

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Lancet, The, 2019
Edward F Mckone, Damian G Downey, Eva Van Braeckel   +2 more
exaly  

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lancet, The, 2013
Dieter Hoelzer
exaly  

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2016
Shaodong Hong, Xuan Wu, Rensheng Wang
exaly  

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Lancet, The, 2010
Johann Sebastian de Bono, Stephane Oudard, Steinbjørn Hansen   +2 more
exaly  

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Lancet, The, 2019
Avraham Eisbruch, Paul M Harari, Erich M Sturgis   +2 more
exaly